Clinical trial · Interventional
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma
NCT07677774CI-TRIAL-00116510recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260911-000001
Summary
Brief summary (as posted)
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glypican-3 | — | UNRESOLVED | — |
| GPC3-targeted PET/CT | — | UNRESOLVED | — |
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GPC3-targeted PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- GPC3-targeted PET/CT
- description
- Each subject receives a single intravenous injection of GPC3-targeted probe and undergoes PET/CT imaging within the specified time.
- interventionNames
- Diagnostic Test: GPC3-targeted PET/CT
Primary outcomes (1)
- measure
- Diagnostic accuracy
- timeFrame
- 1 year
- description
- The sensitivity, specificity, and accuracy of GPC3-targeted PET/CT and CE-MRI in detecting malignant hepatic lesions were calculated and compared.
Secondary outcomes (3)
- measure
- Agreement of BCLC classification with the reference classification
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report); * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. * Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits; Exclusion Criteria: * Lack of contrast-enhanced liver MRI or an interval of more than 14 days between GPC3-targeted PET/CT and contrast-enhanced liver MRI. * Receipt of antitumor treatment between imaging examinations. * The inability or unwillingness of the research participant or legal representative to provide written informed consent. * Inability to complete PET/CT imaging.
References
Publications (0)
Data not yet available
No reference posted for this study.